A Study to Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor
Clinical trial NCT05475184 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05475184
- Sponsor
- Onconic Therapeutics Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-08-31
- Primary completion
- 2024-11-01
- Enrollment
- 58
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.